Edition:
India

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

56.76USD
19 Jan 2018
Change (% chg)

$0.89 (+1.59%)
Prev Close
$55.87
Open
$56.00
Day's High
$56.87
Day's Low
$55.75
Volume
322,822
Avg. Vol
440,357
52-wk High
$99.45
52-wk Low
$45.42

Select another date:

Tue, Dec 19 2017

BRIEF-Rucaparib MAA Referred By CHMP To Scientific Advisory Group On Oncology For Review

* RUCAPARIB MAA FOR THE OVARIAN CANCER TREATMENT INDICATION REFERRED BY CHMP TO SCIENTIFIC ADVISORY GROUP ON ONCOLOGY FOR REVIEW EXPECTED IN FEBRUARY 2018

BRIEF-Clovis Announces Priority Review Designation For Rucaparib Supplemental NDA

* CLOVIS ANNOUNCES PRIORITY REVIEW DESIGNATION FOR RUCAPARIB SUPPLEMENTAL NEW DRUG APPLICATION

BRIEF-Clovis Oncology reports Q3 adjusted shr loss of $1.24

* CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS

BRIEF-Clovis Oncology submits supplemental New Drug Application for rucaparib

* Clovis Oncology submits supplemental New Drug Application for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer

BRIEF-Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

* Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

BRIEF-Clovis Oncology Q2 loss per share $3.88

* Clovis Oncology announces second quarter 2017 operating results

BRIEF-Bristol-Myers, Clovis Oncology announce broad clinical collaboration

* Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types

Select another date: